

Quality Healthcare Within Reach

Your Path To Pharmaceutical
and Chemical Excellence

www.alpha.eu

Alpha 

Your trusted partner in pharmaceutical industry

Olpha is one of the Leading Pharmaceutical companies in the Baltic Region with 50+ years of industry experience

Advantages of Choosing Olpha:

Reliable Supply Chains:

we ensure consistent product availability to meet market demand.

Cost Efficiency:

advantages from lower labor costs, efficient production processes and regionally developed logistics.

High-Quality Standards:

adherence to the highest industry quality and safety standards.

Sustainability:

recognized for sustainability efforts, including a solar panel park to provide 40% of our energy by 2024.

Diverse Product Portfolio:

60 stock keeping units, 25 active pharmaceutical substances, and 20 intermediates, covering essential therapeutic areas.

Product portfolio is continuously developed and expanded. 50+ products approved for portfolio expansion.

Future Plans:

At least 100 million euros investment for 5 years to drive innovation and sustainability.

Commitment to Success:

Choose Olpha for a financially stable partner with extensive therapeutic expertise and a focus on building long-term, successful relationships.

Olpha



Alpha is a part of the AB City group

2nd most valuable local private capital holding in Latvia (748 mn. EUR in 2021)

Holding includes Baltic market leaders in healthcare providers, wholesale, manufacturing, laboratory examination services, and pharmacy chains etc.



Our vision

To improve patient lives worldwide, ranking among the TOP 10 European pharmaceutical companies of our therapeutic groups.



Our mission

Make quality
healthcare
reachable



Alpha in key facts & figures

8,1 mn EUR

investment in
R&D, 2022



**120,25 mn
EUR**

neto
consolidated
turnover, 2022



48 ha

area of the
company in
Olaine



840

professional
employees in
Olpha and
more than
1400
employees in
the Olpha
group



Golden Award

National
Sustainability
Index, 2022 and
2023



> 1 billion
production
capacity for
tablets and
capsules per
year



Olpha



Experienced and professional management team



Juris Bundulis

Chairman of the Board

Juris brings decades of experience in leading major pharmaceutical companies in the Baltics and has a distinguished background in high-level government administration. He joined Olpha in 2021 as the Chairman of the Supervisory Board, and since September 2022, he has held the position of Chairman of the Board. Prior to that, he held prominent positions in other healthcare companies and possesses extensive experience in public administration. Juris has doctoral degrees in both chemistry and biology.



Jānis Leimanis

Board Member, CFO

Jānis is a finance professional with extensive experience in business and finance. He has been a board member of Olpha since June 2021, overseeing financial matters. Previously Jānis has worked in asset management, financial services, and leadership roles in both public and private sectors. He holds a bachelor's degree in mechanics and Mini MBA.



Andris Jegorovs

Board Member, CPO

Andris is a pharmaceutical professional with over 35 years of experience. He has been a board member of Olpha since September 2022 and has been the Production Director since 2021. Andris holds degrees in chemical technology and an MBA, and he is an industry expert with significant contributions to the Latvian Chemical and Pharmaceutical Industry Association (LAĶĪFA) and other NGOs.

Experienced and professional management team



Raimonds Terentjevs
Director of Quality
Management Department

Raimonds, with over 20 years of experience in the chemical and pharmaceutical sectors, serves as the Director of Quality Management at Olpha since 2011, having previously worked as a researcher at the Latvian Institute of Organic Synthesis. Raimonds holds both bachelor's and master's degrees in chemistry.



Elena Bushberg
Executive Director

Elena has over 25 years of experience in international pharmaceutical companies. Her skills include strategy development, leading transformation, and fostering a culture of efficiency. She holds a Global Executive MBA from Duke University – The Fuqua School of Business. Since 2020, she has served as the Executive Director at Olpha.



Ēriks Ivanovskis
Director of Scientific
Office

Ēriks is a seasoned professional with over 25 years of experience in pharmaceutical development, including leadership roles in FDF and API development, regulatory affairs, and contract research and development. He holds a Master's degree in Pharmacy and a Master's degree in Chemistry. Currently serving as the Scientific Office Director at Olpha since September 2022.



Viktorija Zefirova-Tačinska
Change and Development
Process Manager

Viktorija brings extensive healthcare management experience, spanning international and Latvian companies and the public sector. With expertise in change management and corporate culture transformation, she holds an MBA from Riga Technical University and a cardiology specialization from Rīga Stradiņš University. She joined Olpha management team in 2022.



Maksims Vlasenko
Director of Strategic
Development

Maksim, a seasoned pharmaceutical professional, has been advising Olpha's Chairman since March 2023, supervising strategic partnerships and product development, with a diverse background including Business development director role at AB City, investment holding owner of Olpha. He holds a Masters degree in Business administration, was awarded with certificate of Global Management from INSEAD on June 2023 and completed Clinical Trial Management course at the University of Oxford in 2016.



Vladimirs Krušinskis
Director of Technical
Department

Vladimirs, with over 20 years of experience in manufacturing companies, currently serves as the Director of the Technical Department at Olpha. He joined the company in 2012, previously working at AS "Rīgas Farmacitiskā fabrika." Vladimirs holds a bachelor's degree in engineering.



Key pillars of Olpha: research, manufacturing, distribution

Manufacturing

- Active pharmaceutical ingredients & intermediates
- Finished dosage forms: tablets, capsules, powder in sachets



Research

- Development of new active pharmaceutical ingredients and finished drugs
- Development and validation studies of analytical methods
- Clinical trials for the registration



Distribution

- Pharmacies & chains of pharmacies
- Partners & distributors



60+

Stock keeping units in our product portfolio

25+

Active pharmaceutical substances in our product portfolio

30+

New medications submitted for registration in EU markets and UK

Olpha

Product excellence in various therapeutical groups

Neurology

Cardiology

Anti-infective

Allergy

Urology

Oncology

Anti-diabetic

Digestive

NSAID

Hematology

Pulmonary

Endocrine

Olpha is expanding its product portfolio into the existing therapeutic groups as well as adding new medications in new therapeutic groups to its portfolio



We export to

60+

countries worldwide



New drugs in our portfolio

Neurology

Teriflunomide

Zopiclone

Bupropion

Dimethyl Fumarate

Lacosamide

Fingolimod

Cardiology

Atorvastatin+Ezetimibe

Ambrisentan

Edoxaban

Atorvastatin

Rivaroxaban

Macitentan

Rosuvastatin+Ezetimibe

Apixaban

Apixaban ODT

Ezetimibe

Ticagrelor

Sacubitril+Valsartan

Ranolazine

Oncology

Lenalidomide

Abiraterone

Palbociclib

Enzalutamide

Olaparib

Ibrutinib

Cabozantinib

Pomalidomide

Lenvatinib

Nilotinib

Endocrine

Sitagliptin

Vildagliptin+Metformin

Sitagliptin+Metformin

Linagliptin

Vildagliptin

Linagliptin+Metformin

Dapagliflozin

Empagliflozin

Dapagliflozin+Metformin

Allergy

Bilastine

NSAID

Dexketoprofen

Hematology

Eltrombopag

Pulmonary

Nintedanib

Anesthesiology

Sugammadex

Urology

Macro-Nitrofurantoin

Dutasterid+Tamsulosin

Dutasterid

Anti-infective

Caspofungin

Posaconazole



Portfolio for out-licensing

Sr No	Product Name	Pilot BE	Dossier Readiness
1	Rivaroxaban Tabs	Pivotal BE successful	DCP submitted
2	Dapagliflozin + Metformin Tabs	Successful	Q2 2025
3	Linagliptin Tabs	Successful	Q1 2025
4	Dapagliflozin Tabs	Pivotal BE successful	DCP submitted
5	Empagliflozin Tabs	Q3 2024	Q1 2025
6	Enzalutamide Tabs	Q1 2025	Q4 2025
7	Palbociclib Tabs	Q4 2024	Q3 2025
8	Ibrutinib Tabs	Q1 2025	Q1 2026
9	Cabozantinib Tabs	Q1 2025	Q1 2026
10	Olaparib Tabs	Q3 2026	Q3 2026
11	Sacubitril + Valsartan Tabs	Q3 2025	Q2 2026



Quality Assurance and Certifications

EU GMP:
Compliant for APIs
and FDFs



U.S. FDA GMP:
Certified for selected APIs



Australian TDA:
Certified for FDFs

Turkey GMP:
Certified for FDFs

Japanese PMDA
GMP: Certified for
selected APIs

ISO 14001:2015:
Environmental
responsibility



ISO/IEC 17025:2017:
Laboratory excellence

WHO Qualified:
Anti-tuberculosis
meds supplier



Alpha's Contribution to the ESG Principles

Environmental

28.6% Reduction in Carbon Emissions Over the Past 5 Years.

Implementation of Renewable Energy Sources, Including a 3.2 MWh Solar Panel Park.

Renovation of existing external heating and steam pipelines to reduce carbon emissions (heat losses).

Our target is to invest at least 3 million EUR yearly in environmental and energy efficiency projects until 2027.

New Wastewater Treatment System for Sustainable Water Management.

ISO 14001:2015 Certification for Environmental Responsibility and its supplementation by a continuous energy consumption evaluation process.

Social

Active Engagement in Local Communities, Supporting Education, Healthcare, and Science

Employee Well-being Programs, Including Mental Health Support

A Diverse and Inclusive Workforce with 56% Female Representation Among Unit Managers

High Focus on Workplace Safety

Governance

Transparent Corporate Governance Practices and Reporting

Strong Ethical Business Standards, Including Anti-Corruption and AML Measures

A Board of Directors Comprising Industry Experts and Thought Leaders



Full Compliance with Regulatory Standards and Regular Audits

* Figures provided are for December 2022, unless stated otherwise



Golden Award in the National Sustainability Index for Two Consecutive Years (2022 and 2023)





Further in medicine, closer to people!

olpha@olpha.eu

Rūpnīcu Street 5, Olaine,
Olaine District, Latvia

www.olpha.eu

Olpha

